Pfizer unveils interim analysis results from Phase3 BEACON CRC Trial
The results showed significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Oct 19
The results showed significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet…
30 Sep 19
GPA and MPA are two different types of ANCA-associated vasculitis (AAV) that primarily affects small blood vessels of…
25 Sep 19
Jynneos does not contain smallpox or monkeypox causing viruses, and is made from a vaccinia virus that is…
Trinity College scientists claim to have identified a protein linked to lower blood sugar levels that may help…
24 Sep 19
Vitrakvi is used for treating of adult and paediatric patients with solid tumours presenting Neurotrophic Tyrosine Receptor Kinase…
23 Sep 19
Rybelsus is currently being reviewed by various regulatory agencies across the world, including the European Medicines Agency and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Sep 19
Contezolid was associated with fewer drug-related hematologic laboratory adverse events
19 Sep 19
In January 2019, the National Medical Products Administration has approved the use of LINZESS for adults with IBS-C…
18 Sep 19
The US Food and Drug Administration (FDA) has approved Mylan’s Abbreviated New Drug Application (ANDA) for the product
18 Sep 19
The FDA approval marks the first anti-PD-1 therapy tom be approved in combination with a kinase inhibitor for…